BazEkon - The Main Library of the Cracow University of Economics

BazEkon home page

Main menu

Ndayishimiye Costase (Jagiellonian University Medical College), Aji Desmond A. (Jagiellonian University Medical College)
Global Access to Medicine: an Uphill Struggle
Zdrowie Publiczne i Zarządzanie, 2021, t. 19, nr 3-4, s. 104-111, tab., bibliogr. 43 poz.
Choroby, Leki, Patenty, Prawa człowieka
Illness, Medications, Patent, Human rights
Background: The study originated from the authors' coursework in health technology assessment and rational pharmaceutical policy. Purpose: To respond to the question of whether there is a global problem of access to medications by providing differentiated backgrounds and possible solutions or mitigation strategies for boosting the population's access to medications. Method: Thematic content analysis (TCA) was performed on paper-based data. Findings: 39 documents were included, including 22 articles, eleven technical reports, two books, one book chapter, and three websites. Drug accessibility issues affect four major categories - essential, innovative, orphan, and highly-priced medicines. Access to these medications is nevertheless hampered for several reasons, including patents; prohibitive costs; fluctuating production; market unprofitability for rare diseases; and delays in innovative treatments, even in developed countries. Conclusion: Efforts to boost drug access should target all sectors - public, private, and non-governmental - and should forge ties with pharmaceutical firms and key health care institutions. (original abstract)
Full text
  1. World Health Organization, WHO Medicines Strategy 2004-2007: Countries at the Core, World Health Organization, Geneva PP - Geneva 2004:12, (accessed: 27.09.2022).
  2. Ozawa S., Shankar R., Leopold C., and Orubu S., Access to Medicines through Health Systems in Low-and Middle-Income Countries, "Health Policy Plan." 2019; 34, no. Supplement_3: III1-III3, doi: 10.1093/heapol/czz119.
  3. World Health Organization, Equitable Access to Essential Medicines: a Framework for Collective Action, "WHO Policy Perspect. Med." 2004; 4: 1-6.
  4. Aitken M., Kleinrock M., Simorellis A., and Nass D., The Global Use of Medicine in 2019 and Outlook to 2023, "IQVIA Inst. Hum. Data Sci." 2019; no. January: 1-56.
  5. Rajkumar S.V., The High Cost of Prescription Drugs: Causes and Solutions, "Blood Cancer J." 2020; 10 (6), doi: 10.1038/s41408-020-0338-x.
  6. Miller F.A., Alvarado K., Incorporating Documents into Qualitative Nursing Research, "J. Nurs. Scholarsh." 2005; 37 (4): 348-353.
  7. Howell M.C., Prevenier W., From Reliable Sources: An Introduction to Historical Methods, Cornell University Press, 2001.
  8. Hunter K.E. et al., Searching Clinical Trials Registers: Guide for Systematic Reviewers, "BMJ" 2022; 377: e068791, doi: 10.1136/bmj-2021-068791.
  9. Flynn S., Hollis A., Palmedo M., An Economic Justification for Open Access to Essential Medicine Patents in Developing Countries, "J. Law, Med. Ethics" 2009; 37 (2): 184-208.
  10. Collier R., Rapidly Rising Clinical Trial Costs Worry Researchers, "CMAJ" 2009; 180 (3): 277-278, doi: 10.1503/cmaj.082041.
  11. Johnston S.C., Hauser S.L., Clinical Trials: Rising Costs Limit Innovation, "Ann. Neurol." 2007; 62 (6): 6-7, doi: 10.1002/ana.21329.
  12. Sharma A., Jacob A., Tandon M., Kumar D., Orphan Drug: Development Trends and Strategies, "J. Pharm. Bioallied Sci." 2010; 2 (4): 290, doi: 10.4103/0975-7406.72128.
  13. Franco P., Orphan Drugs: The Regulatory Environment, "Drug Discov. Today" 2013; 18 (3-4): 163-172, doi: 10.1016/J.DRUDIS.2012.08.009.
  14. Blankart C.R., Stargardt T., Schreyögg J., Availability of and Access to Orphan Drugs: An International Comparison of Pharmaceutical Treatments for Pulmonary Arterial Hypertension, Fabry Disease, Hereditary Angioedema and Chronic Myeloid Leukaemia, "Pharmacoeconomics" 2011; 29 (1): 63-82, doi: 10.2165/11539190-000000000-00000.
  15. Aagaard L., Kristensen K., Access to Cross-Border Health Care Services for Patients with Rare Diseases in the European Union, "Orphan Drugs Res. Rev." 2014; 4: 39, doi: 10.2147/ODRR.S58268.
  16. Garau M., Mestre-Ferrandiz J., Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries, "OHE Brief." 2009; 52: 1-32.
  17. Diabetes TL. Spotlight on Rare Diseases, "The Lancet Diabetes & Endocrinology" 2019; 7 (2):75.
  18. Villa S., Compagni A., Reich M.R., Orphan Drug Legislation: Lessons for Neglected Tropical Diseases, "Int. J. Health Plann. Manage" 2009; 24 (1): 27-42, doi: 10.1002/HPM.930.
  19. Chan A.Y.L. et al., Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis, "Value Heal." 2020; 23 (12): 1580-1591, doi: 10.1016/J.JVAL.2020.06.020.
  20. Ahmadiani S., Nikfar S., Challenges of Access to Medicine and The Responsibility of Pharmaceutical Companies: a Legal Perspective, "DARU J. Pharm. Sci." 2016; 24 (1): 1-7, doi: 10.1186/S40199-016-0151-Z.
  21. Kantarjian H., Rajkumar S.V., Why are Cancer Drugs so Expensive in the United States, and What are The Solutions?, "Mayo Clin. Proc." 2015; 90 (4): 500-504, doi: 10.1016/j.mayocp.2015.01.014.
  22. Masiga J., Essential Drugs Concept: Is It Still Relevant in Our Situation Today, "Meds Updat." 2010; 17: 2-8.
  23. Loyse al., Cryptococcal Meningitis: Improving Access to Essential Antifungal Medicines in Resource-Poor Countries, "Lancet Infect. Dis." 2013; 13 (7): 629-637.
  24. Nchako E., Bussell S., Nesbeth C., Odoh C., Barriers to The Availability and Accessibility of Controlled Medicines for Chronic Pain in Africa, "Int. Health" 2018; 10, (2): 71-77.
  25. Pe B., Chirac P., Trouiller P., and Pinel J., Access to Essential Drugs in Poor Countries, "JAMA" 1999; 281 (4): 361-367.
  26. Pécoul al., Long-acting Chloramphenicol versus Intravenous Ampicillin for Treatment of Bacterial Meningitis, "Lancet" 1991; 338 (8771): 862-866, doi: 10.1016/0140-6736(91)91511-R.
  27. Grover A., Citro B., Mankad M., Lander F., Pharmaceutical Companies and Global Lack of Access to Medicines: Strengthening Accountability under The Right to Health, "J. Law. Med. Ethics" 2012, 40 (2): 234-250, doi: 10.1111/J.1748-720X.2012.00661.X.
  28. World Health Organization, Pharmaceutical Industry, Trade, Foreign Policy, Diplomacy and Health, Geneva 2013.
  29. World Health Organisation (WHO), Towards Access 2030: WHO Medicines and Health Products Programme Strategic Framework 2016-2030, Geneva 2017.
  30. EUROPE and W. H. O., Access to New Medicines in Europe: Technical Review of Policy Initiatives and Opportunities for Research, Copenhagen 2015.
  31. European Organisation for Rare Dieases, Rare Diseases: Understanding This Public Health Priority, Paris 2005.
  32. Toreele E., Usdin M., and Chirac P., A Needs-Based Pharmaceutical R&D Agenda for Neglected Diseases, Geneva 2004.
  33. World Health Organization, The Rational Use of Drugs: Report of the Conference of Experts, Nairobi, 25-29 November 1985, Geneva 1985.
  34. World Health Organization, Promoting Rational Use of Medicines: Core Components, Gneva 2002.
  35. W.H.O and Europe, Expert Meeting on Market High-priced Innovative Medicines, Brussels 2020.
  36. Pan American Health Organization and Regional Office of the World Health Organization, Access to High-Cost Medicines in the Americas: Situation, Challenges and Perspectives, Washington 2010.
  37. European Federation of Pharmaceutical Industries and Associations, The Root Cause of Unavailability and Delay to Innovative Medicines: Reducing the Time before Patients Have Access to Innovative Medicines, Brussels 2020.
  38. Pogge T., Rimmer M., Rubenstein K., Introduction: Access to Essential Medicines: Public Health and International, in: Incentives for Global Public Health: Patent Law and Access to Essential Medicines Connecting International Law with Public Law], T. Pogge, M. Rimmer, and Rubenstein, Eds., Cambridge University Press, 2010: 1-32.
  39. Persistent Market Reaserch, Innovative Drugs Market: Global Industry Analysis and Forecast to 2020, (accessed: 8.01.2022).
  40. UN Human Rights Office of the High Commissioner, Special Rapporteur on the right to physical and mental health, Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health, 2020, (accessed: 8.01.2022).
  41. Mtech Team, Challenges for Orphan Medicines Entering the European Market - Part 4: Operational Challenges, 2021, (accessed: 8.01.2022).
  42. Hodder I., Hutson S., Reading the Past: Current Approaches to Interpretation in Archaeology, Cambridge University Press, 2003.
  43. Thurmond V.A., The Point of Triangulation, "J. Nurs. Scholarsh." 2001; 33 (3): 253-258.
Cited by
Share on Facebook Share on Twitter Share on Google+ Share on Pinterest Share on LinkedIn Wyślij znajomemu